latest news releases from the newsroom
BSD Medical Corporation
BSD Medical Anticipates Patent for New Device to Optimize Treatments with Radiation
SALT LAKE CITY, July 26, 2005 (PRIMEZONE) -- BSD Medical Corp. (AMEX:BSM) today announced that the company has received "official notice of allowance" for a new patent that is expected to be issued by the U.S. Patent Office. The patent is being secured as the basis for a new disposable device that would enable the use of simultaneous brachytherapy (interstitial radiation) and microwave hyperthermia therapy, employing BSD's existing systems. Current technology allows only sequential treatments.
Harsco Reports Record Diluted EPS of $0.99 for the 2005 Second Quarter, Up 32%; Company Raises 2005 Earnings Guidance
HARRISBURG, Pa., July 26, 2005 (PRIMEZONE) -- Worldwide industrial services and products company Harsco Corporation (NYSE:HSC) today reported record second quarter diluted earnings per share (EPS) from continuing operations of $0.99 for the second quarter of 2005, an increase of 32 percent from $0.75 in the second quarter of 2004. Income from continuing operations, also a record, was up 35 percent to $41.8 million from $31.0 million last year. Overall operating margins improved by approximately 140 basis points to 10.7 percent, up from 9.3 percent in last year's comparable quarter. Second quarter sales were up 13 percent to a record $696 million, compared with $618 million in the same period last year. Positive foreign currency translation contributed approximately $14 million to this year's second quarter sales and $1.3 million to pre-tax income.
eTelcharge.com Announces Spanish Version of the Website
DESOTO, Texas, July 26, 2005 (PRIMEZONE) -- eTelcharge.com (Pink Sheets:ETLC), www.etelcharge.com a financial diversified merchant service company, today announced that it will launch a Spanish version of its website on August 4, 2005, thus expanding its online presence in order to reach out to the millions of Spanish speaking Internet users.
DOR BioPharma, Inc
DOR BioPharma and Dowpharma Enter Into a Joint Development Agreement for BT-VACC, DOR's Oral Vaccine Against Botulinum Toxin Poisoning
MIAMI, July 26, 2005 (PRIMEZONE) -- DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") today announced it has entered into a joint development agreement with Dowpharma(sm), a business unit of The Dow Chemical Company (NYSE:DOW), to advance the development of DOR's proprietary oral botulinum vaccine, BT-VACC(tm). BT-VACC(tm) is designed to protect against exposure to botulinum toxin, which is one of five Category A bioterrorism threats identified by the U.S. government.